BioGX, a provider of molecular diagnostic solutions, launched a point-of-care (POC) CE-Marked, three gene multiplex COVID test on its pixl platform.
The test utilizes BioGX’s Xfree direct sample testing chemistry that is included in its U.S. FDA emergency use authorized Xfree COVID-19 Direct RT-PCR test. This new multi-gene COVID-19 test targets the N1, RdRp, and M gene regions for greater redundancy in detecting SARS-CoV-2 emerging variants.
This POC test is simple to use and only requires the addition of one drop of sample added directly to the freeze-dried Xfree chemistry.
The BioGX pixl16 is a small, portable, 4-channel, 16-well real-time PCR platform that supports turnaround times of less than an hour for up to 16 samples. Results interpretation and reporting are integrated within the easy-to-use touchpad-based pixl instrument.
“Pixl, combined with our unique Xfree chemistry offers our customers the ease-of-use and affordability of antigen-based testing with the superior sensitivity and specificity of real-time PCR testing,” says Shazi Iqbal, CEO of BioGX.
Building upon the success of its Xfree direct sample addition technology, BioGX is developing a pipeline of Xfree-pixl tests that will enable simple and affordable POC PCR testing. As with all BioGX tests, the Xfree COVID-19 3-gene Direct Sample RT-PCR kits ship globally at ambient temperature.
